NASDAQ:BCTX BriaCell Therapeutics (BCTX) Stock Price, News & Analysis $0.79 +0.04 (+5.32%) (As of 10:45 AM ET) Add Compare Share Share Today's Range$0.72▼$0.8050-Day Range$0.55▼$1.4852-Week Range$0.52▼$7.59Volume147,372 shsAverage Volume205,293 shsMarket Capitalization$14.44 millionP/E RatioN/ADividend YieldN/APrice Target$18.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get BriaCell Therapeutics alerts: Email Address BriaCell Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside2,200.3% Upside$18.00 Price TargetShort InterestHealthy3.00% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.39) to ($1.00) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.16 out of 5 starsMedical Sector552nd out of 924 stocksPharmaceutical Preparations Industry248th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingBriaCell Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageBriaCell Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about BriaCell Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.00% of the float of BriaCell Therapeutics has been sold short.Short Interest Ratio / Days to CoverBriaCell Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BriaCell Therapeutics has recently decreased by 18.44%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBriaCell Therapeutics does not currently pay a dividend.Dividend GrowthBriaCell Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BCTX. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for BriaCell Therapeutics this week, compared to 0 articles on an average week.Search InterestOnly 3 people have searched for BCTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added BriaCell Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BriaCell Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders21.77% of the stock of BriaCell Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 15.42% of the stock of BriaCell Therapeutics is held by institutions.Read more about BriaCell Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BriaCell Therapeutics are expected to grow in the coming year, from ($1.39) to ($1.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BriaCell Therapeutics is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BriaCell Therapeutics is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about BriaCell Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Darwin2024's Must-Watch Stocks!Welcome to a year of unparalleled opportunities! Dive into our exclusive guide, "9 Stocks Set to Soar," meticulously selected to elevate your portfolio in 2024. Step into 2024 with confidence and the right assets at your fingertips. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time. [Unlock Your Report Now] About BriaCell Therapeutics Stock (NASDAQ:BCTX)BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.Read More BCTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BCTX Stock News HeadlinesAugust 15, 2024 | investing.comBriacell Therapeutics Corp (BCT)July 18, 2024 | globenewswire.comBriaCell Quadruples Progression Free Survival (PFS) in Patient with “Eye-Bulging” Metastatic Breast CancerAugust 22, 2024 | Insiders Exposed (Ad)Has Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.June 3, 2024 | globenewswire.comBriaCell Presents Clinical Efficacy Data at ASCO 2024May 24, 2024 | globenewswire.comBriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024May 17, 2024 | globenewswire.comBriaCell Therapeutics Announces Closing of $5.0 Million Registered Direct OfferingMay 15, 2024 | globenewswire.comBriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct OfferingApril 24, 2024 | globenewswire.comBriaCell Announces Oral and Poster Presentations at ASCO 2024August 22, 2024 | Insiders Exposed (Ad)Has Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.April 10, 2024 | globenewswire.comBriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate CancerApril 9, 2024 | finance.yahoo.comBriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACRMarch 20, 2024 | sg.finance.yahoo.comBriaCell Therapeutics Corp. (BCTX)March 7, 2024 | globenewswire.comBriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer ImmunotherapiesMarch 6, 2024 | globenewswire.comBriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR ConferenceFebruary 27, 2024 | finance.yahoo.comBriaCell Provides Update on Alleged Illegal Trading of Public SecuritiesFebruary 27, 2024 | globenewswire.comBriaCell Provides Update on Alleged Illegal Trading of Public SecuritiesFebruary 14, 2024 | finance.yahoo.comBriaCell Therapeutics Corp. (BCTX) stock forecast and price targetJanuary 30, 2024 | finance.yahoo.comBriaCell Therapeutics Corp. Announces Results of Shareholder MeetingSee More Headlines Receive BCTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BriaCell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings6/14/2024Today8/22/2024Next Earnings (Estimated)10/23/2024Fiscal Year End7/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BCTX CUSIPN/A CIK1610820 Webwww.briacell.com Phone(604) 921-1810Fax604-921-1898Employees16Year FoundedN/APrice Target and Rating Average Stock Price Target$18.00 High Stock Price Target$18.00 Low Stock Price Target$18.00 Potential Upside/Downside+2,200.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,300,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-37.35% Debt Debt-to-Equity RatioN/A Current Ratio0.82 Quick Ratio0.82 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.24) per share Price / Book-3.26Miscellaneous Outstanding Shares18,285,000Free Float14,304,000Market Cap$14.31 million OptionableOptionable Beta1.29 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. William V. Williams M.D. (Age 69)CEO, President & Director Comp: $785.3kMr. Gadi Levin B.Com. (Age 51)C.A., CPA, M.B.A., CFO & Corporate Secretary Comp: $304.46kDr. Miguel A. Lopez-Lago Ph.D. (Age 55)Chief Scientific Officer Comp: $298.9kDr. Giuseppe Del Priore M.D. (Age 62)M.P.H., MPH, Chief Medical Officer Comp: $492.5kDr. Charles Louis Wiseman FACP (Age 78)M.D., Founder, Principal Research Advisor & Member of Scientific Advisory Board Comp: $241.14kKey CompetitorsLantern PharmaNASDAQ:LTRNCarisma TherapeuticsNASDAQ:CARMvTv TherapeuticsNASDAQ:VTVTSyros PharmaceuticalsNASDAQ:SYRSFibroBiologicsNASDAQ:FBLGView All Competitors BCTX Stock Analysis - Frequently Asked Questions How have BCTX shares performed this year? BriaCell Therapeutics' stock was trading at $5.85 at the beginning of 2024. Since then, BCTX stock has decreased by 86.6% and is now trading at $0.7825. View the best growth stocks for 2024 here. How were BriaCell Therapeutics' earnings last quarter? BriaCell Therapeutics Corp. (NASDAQ:BCTX) released its quarterly earnings data on Friday, June, 14th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.66. When did BriaCell Therapeutics IPO? BriaCell Therapeutics (BCTX) raised $15 million in an IPO on Wednesday, February 24th 2021. The company issued 3,300,000 shares at a price of $4.25-$5.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO. How do I buy shares of BriaCell Therapeutics? Shares of BCTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BCTX) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredThis Crypto Is Set to Explode in AugustWith the 2024 Bitcoin Halving, there's a potential HUGE bull run for altcoins. While everyone's chasing the...Crypto 101 Media | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredSilver Grab of the Decade?In a groundbreaking move, J.P. Morgan now possesses the largest amount of physical silver in recorded history…...Colonial Metals | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredThis One stock is all you need...What if you could ignore 99% of the stock market... And retire on just ONE ticker?Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BriaCell Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share BriaCell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
